Cargando…
Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants
OBJECTIVE: Mutations in ANXA11 cause amyotrophic lateral sclerosis (ALS) and have recently been identified as a cause of multisystem proteinopathy and adult‐onset muscular dystrophy. These conditions are adult‐onset diseases and result from the substitution of Aspartate 40 (Asp40) for an apolar resi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014011/ https://www.ncbi.nlm.nih.gov/pubmed/36651622 http://dx.doi.org/10.1002/acn3.51731 |
_version_ | 1784906905626345472 |
---|---|
author | Natera‐de Benito, Daniel Olival, Jonathan Garcia‐Cabau, Carla Jou, Cristina Roldan, Mònica Codina, Anna Expósito‐Escudero, Jessica Batlle, Cristina Carrera‐García, Laura Ortez, Carlos Salvatella, Xavier Palau, Francesc Nascimento, Andrés Hoenicka, Janet |
author_facet | Natera‐de Benito, Daniel Olival, Jonathan Garcia‐Cabau, Carla Jou, Cristina Roldan, Mònica Codina, Anna Expósito‐Escudero, Jessica Batlle, Cristina Carrera‐García, Laura Ortez, Carlos Salvatella, Xavier Palau, Francesc Nascimento, Andrés Hoenicka, Janet |
author_sort | Natera‐de Benito, Daniel |
collection | PubMed |
description | OBJECTIVE: Mutations in ANXA11 cause amyotrophic lateral sclerosis (ALS) and have recently been identified as a cause of multisystem proteinopathy and adult‐onset muscular dystrophy. These conditions are adult‐onset diseases and result from the substitution of Aspartate 40 (Asp40) for an apolar residue in the intrinsically disordered domain (IDD) of ANXA11. Some ALS‐related variants are known to affect ANXA11 IDD; however, the mechanism by which the myopathy occurs is unknown. METHODS: Genetic analysis was performed using WES‐trio. For the study of variant pathogenicity, we used recombinant proteins, muscle biopsy, and fibroblasts. RESULTS: Here we describe an individual with severe and rapidly progressive childhood‐onset oculopharyngeal muscular dystrophy who carries a new ANXA11 variant at position Asp40 (p.Asp40Ile; c.118_119delGAinsAT). p.Asp40Ile is predicted to enhance the aggregation propensity of ANXA11 to a greater extent than other changes affecting this residue. In vitro studies using recombinant ANXA11(p.Asp40Ile) showed abnormal phase separation and confirmed this variant is more aggregation‐prone than the ALS‐associated variant ANXA11(p.Asp40Gly). The study of the patient's fibroblasts revealed defects in stress granules dynamics and clearance, and muscle histopathology showed a myopathic pattern with ANXA11 protein aggregates. Super‐resolution imaging showed aggregates expressed as pearl strips or large complex structures in the sarcoplasm, and as layered subsarcolemmal chains probably reflecting ANXA11 multifunctionality. INTERPRETATION: We demonstrate common pathophysiology for disorders associated with ANXA11 Asp40 allelic variants. Clinical phenotypes may result from different deleterious impacts of variants upon ANXA11 stability against aggregation, and differential muscle or motor neuron dysfunction expressed as a temporal and tissue‐specific continuum. |
format | Online Article Text |
id | pubmed-10014011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100140112023-03-15 Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants Natera‐de Benito, Daniel Olival, Jonathan Garcia‐Cabau, Carla Jou, Cristina Roldan, Mònica Codina, Anna Expósito‐Escudero, Jessica Batlle, Cristina Carrera‐García, Laura Ortez, Carlos Salvatella, Xavier Palau, Francesc Nascimento, Andrés Hoenicka, Janet Ann Clin Transl Neurol Research Articles OBJECTIVE: Mutations in ANXA11 cause amyotrophic lateral sclerosis (ALS) and have recently been identified as a cause of multisystem proteinopathy and adult‐onset muscular dystrophy. These conditions are adult‐onset diseases and result from the substitution of Aspartate 40 (Asp40) for an apolar residue in the intrinsically disordered domain (IDD) of ANXA11. Some ALS‐related variants are known to affect ANXA11 IDD; however, the mechanism by which the myopathy occurs is unknown. METHODS: Genetic analysis was performed using WES‐trio. For the study of variant pathogenicity, we used recombinant proteins, muscle biopsy, and fibroblasts. RESULTS: Here we describe an individual with severe and rapidly progressive childhood‐onset oculopharyngeal muscular dystrophy who carries a new ANXA11 variant at position Asp40 (p.Asp40Ile; c.118_119delGAinsAT). p.Asp40Ile is predicted to enhance the aggregation propensity of ANXA11 to a greater extent than other changes affecting this residue. In vitro studies using recombinant ANXA11(p.Asp40Ile) showed abnormal phase separation and confirmed this variant is more aggregation‐prone than the ALS‐associated variant ANXA11(p.Asp40Gly). The study of the patient's fibroblasts revealed defects in stress granules dynamics and clearance, and muscle histopathology showed a myopathic pattern with ANXA11 protein aggregates. Super‐resolution imaging showed aggregates expressed as pearl strips or large complex structures in the sarcoplasm, and as layered subsarcolemmal chains probably reflecting ANXA11 multifunctionality. INTERPRETATION: We demonstrate common pathophysiology for disorders associated with ANXA11 Asp40 allelic variants. Clinical phenotypes may result from different deleterious impacts of variants upon ANXA11 stability against aggregation, and differential muscle or motor neuron dysfunction expressed as a temporal and tissue‐specific continuum. John Wiley and Sons Inc. 2023-01-18 /pmc/articles/PMC10014011/ /pubmed/36651622 http://dx.doi.org/10.1002/acn3.51731 Text en © 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Natera‐de Benito, Daniel Olival, Jonathan Garcia‐Cabau, Carla Jou, Cristina Roldan, Mònica Codina, Anna Expósito‐Escudero, Jessica Batlle, Cristina Carrera‐García, Laura Ortez, Carlos Salvatella, Xavier Palau, Francesc Nascimento, Andrés Hoenicka, Janet Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants |
title | Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants |
title_full | Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants |
title_fullStr | Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants |
title_full_unstemmed | Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants |
title_short | Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants |
title_sort | common pathophysiology for anxa11 disorders caused by aspartate 40 variants |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014011/ https://www.ncbi.nlm.nih.gov/pubmed/36651622 http://dx.doi.org/10.1002/acn3.51731 |
work_keys_str_mv | AT nateradebenitodaniel commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT olivaljonathan commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT garciacabaucarla commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT joucristina commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT roldanmonica commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT codinaanna commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT expositoescuderojessica commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT batllecristina commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT carreragarcialaura commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT ortezcarlos commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT salvatellaxavier commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT palaufrancesc commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT nascimentoandres commonpathophysiologyforanxa11disorderscausedbyaspartate40variants AT hoenickajanet commonpathophysiologyforanxa11disorderscausedbyaspartate40variants |